CN116589434A - 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 - Google Patents
一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 Download PDFInfo
- Publication number
- CN116589434A CN116589434A CN202310577912.4A CN202310577912A CN116589434A CN 116589434 A CN116589434 A CN 116589434A CN 202310577912 A CN202310577912 A CN 202310577912A CN 116589434 A CN116589434 A CN 116589434A
- Authority
- CN
- China
- Prior art keywords
- vomeropherin
- pharmaceutical composition
- xinafoate
- crystalline form
- orally disintegrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000013078 crystal Substances 0.000 title claims abstract description 16
- 229950000339 xinafoate Drugs 0.000 claims abstract description 25
- 239000006191 orally-disintegrating tablet Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical class N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 229940093257 valacyclovir Drugs 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007810 chemical reaction solvent Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 235000019640 taste Nutrition 0.000 abstract description 8
- 210000000214 mouth Anatomy 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000873 masking effect Effects 0.000 abstract description 3
- 210000001779 taste bud Anatomy 0.000 abstract description 3
- -1 1- [2- (2, 4-dimethylphenylsulfanyl) phenyl ] piperazine 1-hydroxy 2-naphthoic acid Chemical compound 0.000 abstract description 2
- 150000003839 salts Chemical group 0.000 description 18
- 239000002253 acid Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 229910052956 cinnabar Inorganic materials 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960002263 vortioxetine Drugs 0.000 description 3
- DVWQNBIUTWDZMW-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalen-2-ol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=CC=CC2=C1 DVWQNBIUTWDZMW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- AKGGYBADQZYZPD-UHFFFAOYSA-N benzyl acetone Natural products CC(=O)CCC1=CC=CC=C1 AKGGYBADQZYZPD-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940039293 trintellix Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- VNGRUFUIHGGOOM-UHFFFAOYSA-N vortioxetine hydrobromide Chemical compound Br.CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 VNGRUFUIHGGOOM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了伏硫西汀昔萘酸盐(1‑[2‑(2,4‑二甲基苯基硫基)苯基]哌嗪1‑羟基2‑萘甲酸)的晶型A及其制备方法。本发明还提供了包括该晶型的药物组合物及其在药物制备中的应用。本发明将伏硫西汀昔萘酸盐制成口崩片,在快速崩解释放的同时,减少其在口腔中的溶解度,使其达不到味蕾阈值,以达到掩味目的。且操作简单,易于实现产业化。
Description
技术领域
本发明属于医药领域,具体涉及一种伏硫西汀昔萘酸盐晶型A及其制备方法与应用。
背景技术
抑郁症是大脑活动异常或下丘脑等参与情绪调节的脑区功能障碍所引发的一类精神障碍疾病。据估计,全球有5.0%的成年人患有抑郁症。以情感低落、思维迟缓、以及言语动作减少、迟缓为典型症状。
伏硫西汀(Vortioxetine),又名沃替西汀,化学名称1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪,1-[2-[(2,4-Dimethylphenyl)thio]phenyl]piperazine,其化学结构式如下:
伏硫西汀是一种新型的多模式抗抑郁剂,目前上市的盐型包括氢溴酸盐和DL-乳酸盐,剂型是片剂及滴剂。伏硫西汀口服吸收良好,但吸收较慢,口服用药后的达峰时间为7~11小时,绝对生物利用度为75%,消除半衰期为66小时,表明该药物消除周期长,作用持久,但是吸收较慢,即便是口服溶液也表现出与片剂相近的达峰时间;同时,伏硫西汀味道苦涩,会在一定程度上影响用药依从性。
口腔速崩片(Orally disintegrating tablets,简称ODT)是一种新型口服剂型,该类制剂可在无水的条件下(或仅有少量水存在)于口腔中快速崩解,随吞咽动作进入消化道,在口腔内无粘膜吸收,体内吸收、代谢过程与普通片剂一致。ODT与普通制剂相比,有服用方便、吸收快、生物利用度高、对消化道黏膜刺激性小等优点。将伏硫西汀和昔萘酸结合,制成难溶性盐,将伏硫西汀昔萘酸盐制成口崩片,在快速崩解释放的同时,减少其在口腔中的溶解度,使其达不到味蕾阈值,以达到掩味目的。
昔萘酸,化学名称1-羟基-2-萘甲酸,其化学结构式如下:
昔萘酸是一种可生成盐类的有机酸,经常用于药物制剂中以便制备药物的难溶性盐,目前已上市的药物有昔萘酸沙美特罗。目前暂无将昔萘酸和伏硫西汀制成盐,及其盐的晶型研究的相关报道。
发明内容
本发明对伏硫西汀盐进行了研究,提供一种伏硫西汀昔萘酸盐晶型A,得到的晶型纯度高(>99.5%),干燥后硬度小易粉碎,易于药物组合物的配制和使用。
本发明提供了伏硫西汀昔萘酸盐,该物质结构式如下:
所述的盐中,伏硫西汀与昔萘酸的摩尔比为1:1。
本发明所述的伏硫西汀昔萘酸盐为晶型A,该晶型的X射线粉末衍射图中,在2θ(°)为5.94±0.2、6.99±0.2、10.97±0.2、16.25±0.2、22.01±0.2位置有衍射峰。
进一步地,晶型A还在2θ(°)值为11.93±0.2、14.02±0.2、17.48±0.2、17.98±0.2、18.63±0.2、21.21±0.2、22.23±0.2的一处或多处有衍射峰。或者该晶型的X射线粉末衍射图谱中在2θ(°)为19.67±0.2、24.06±0.2、24.41±0.2、25.02±0.2、25.75±0.2、26.04±0.2、28.39±0.2、28.64±0.2、28.84±0.2、31.77±0.2的一处或多处有衍射峰。
本发明所公开的伏硫西汀昔萘酸盐晶型A,其制备方法如下:将伏硫西汀溶于反应溶剂中,20℃~60℃条件下加入昔萘酸进行反应,反应结束后,降至室温,过滤分离得到固体,经真空干燥得伏硫西汀昔萘酸盐。
所述的反应溶剂选自醇类、酮类、腈类、醚类、二氯甲烷、二甲基亚砜、N,N-二甲基乙酰胺、N,N-二甲基甲酰胺中的一种或几种,或其与水的组合物。
优选的,所述的反应溶剂选自无水甲醇、无水乙醇、95%乙醇、异丙醇、苯甲醇、丙酮或乙腈。更优选为无水乙醇。
进一步地,本发明还提供了一种伏硫西汀的药物组合物,采用本发明所述伏硫西汀昔萘酸盐晶型A为药物主要活性成分。
所述药物组合物可以为片剂、胶囊剂、口服混悬液、注射剂。
本发明所述的口崩片,包含填充剂、崩解剂、助流剂、润滑剂中的一种或几种。
优选的,所述填充剂选自微晶纤维素(MCC)、微粉乙基纤维素、甘露醇、葡萄糖、山梨醇、乳糖和玉米淀粉中的一种或几种;所述崩解剂选自交联羧甲基纤维素钠(cCMC-Na)、交联聚维酮(PVPP)、羧甲基淀粉钠(CMC-Na)、低取代羟丙纤维素(L-HPC)中的一种或几种;所述助流剂为二氧化硅、微粉硅胶的一种或几种;所述润滑剂为滑石粉、硬脂酸镁中的一种或两种。
本发明口崩片的制备方法如下:
1)伏硫西汀昔萘酸盐晶型A微粉化处理至一定的粒度分布。
2)微粉后的原辅料过筛混匀后,再与润滑剂过筛混匀 ;
3)使用粉末直压法制备昔萘酸伏硫西汀片。
本发明优点:
(1)本发明所述伏硫西汀昔萘酸盐晶型A,将伏硫西汀和昔萘酸结合,制成难溶性盐,提高了药物稳定性。与市售产品“TRINTELLIX(国内:心达悦)”相比,本发明将伏硫西汀昔萘酸盐制成口崩片,在快速崩解释放的同时,减少其在口腔中的溶解度,使其达不到味蕾阈值,以达到掩味目的。
(2)本发明采用粉末直压法便能将片剂压制成型,减少了产品不稳定的风险,且操作简单,易于实现产业化。
附图说明
图1是本发明实施例1中伏硫西汀昔萘酸盐晶型A的1H-NMR图谱。
图2是本发明实施例1中伏硫西汀昔萘酸盐晶型A的MS(ESI+)图谱。
图3是本发明实施例1中伏硫西汀昔萘酸盐晶型A的MS(ESI-)图谱。
图4是本发明实施例1中伏硫西汀昔萘酸盐晶型A的X-射线粉末衍射图谱。
图5是本发明实施例1中伏硫西汀昔萘酸盐晶型A的差示扫描量热图谱。
图6是本发明实施例1中伏硫西汀昔萘酸盐晶型A的红外光谱图。
图7是本发明实施例3中伏硫西汀昔萘酸盐晶型A的X-射线粉末衍射图谱。
具体实施方式
以下结合具体实施方式和范例性实施例对本发明作进一步说明,但这些说明并不能理解为对本发明的任何限制。本领域技术人员理解,在不偏离本发明精神和范围的情况下,可以对本发明技术方案及其实施方式进行多种的等价替换,修饰或改进,这些均落入本发明的范围内。本发明的保护范围以所附权利要求为准。具体实施例阐述如下:
实施例1
伏硫西汀昔萘酸盐晶型A的制备:
将伏硫西汀(5.0011g,16.75mmol)和无水乙醇75mL加入到反应瓶中,搅拌溶解,溶液加热至50℃后加入昔萘酸(3.1523g,16.75 mmol),溶解后继续搅拌2h,反应结束后降至室温,抽滤,滤饼用无水乙醇洗涤三次,40~50℃减压干燥,得伏硫西汀昔萘酸盐晶型A7.3214g,收率89.80%。使用1H-NMR和MS分析伏硫西汀昔萘酸盐结构。1H-NMR化学位移记录在(所有值以ppm计)δ9.127(s,2H),8.200(dd,1H),7.750(dd,1H),7.709(dd,1H),7.455(ddd,1H),7.399–7.316(m,2H),7.247(d, 1H),7.188–7.082(m,3H),7.017(d,1H),6.966(td,1H),6.425(dd,1H),3.277(t,4H),3.199(d, 4H),2.326(s,3H),2.247(s,3H)。MS(ESI):299.2(正离子模式),186.9(负离子模式)。
晶体的1H-NMR图谱如图1所示;MS图谱如图2和图3所示;X-射线粉末衍射图谱如图4所示;差示扫描量热图谱如图5所示;红外光谱如图6所示。
实施例2
伏硫西汀昔萘酸盐晶型A的制备
将伏硫西汀(0.6001g,2.01mmol)和甲醇10mL加入到反应瓶中,搅拌溶解,溶液加热至50℃后加入昔萘酸(0.3783g, 2.01mmol),搅拌溶解,向上述溶液中滴加注射用水7ml,析出固体,继续搅拌2h,反应结束后降至室温,抽滤,滤饼用注射用水洗涤三次,40~50℃减压干燥,得伏硫西汀昔萘酸盐晶型A。
实施例3
伏硫西汀昔萘酸盐晶型A的制备
将伏硫西汀(1.0003g,3.35mmol)和二甲基亚砜9mL加入到反应瓶中,搅拌溶解,溶液加热至50℃后加入昔萘酸(0.6292g,3.34mmol),搅拌溶解,向上述溶液中滴加注射用水7ml,析出固体,继续搅拌2h,反应结束后降至室温,抽滤,滤饼用注射用水洗涤三次,40~50℃减压干燥,得伏硫西汀昔萘酸盐晶型A。晶体的X-射线粉末衍射图谱如图7所示。
实施例4
伏硫西汀昔萘酸盐晶型A的制备
将伏硫西汀(1.0003g,3.35mmol)和丙酮9mL加入到反应瓶中,搅拌溶解,溶液加热至50℃后加入昔萘酸(0.6300g,3.34mmol),搅拌溶解,析出固体,继续搅拌2h,反应结束后降至室温,抽滤,滤饼用丙酮洗涤三次,40~50℃减压干燥,得伏硫西汀昔萘酸盐晶型A。
应用实施例1 伏硫西汀昔萘酸盐药物组合物口崩片及其制备工艺
1、处方 伏硫西汀昔萘酸盐口崩片的处方见表1
表 处方用量表
2、制备工艺
(1)通过气流粉碎机将伏硫西汀昔萘酸盐粉碎,控制粒径D90<20μm;
(2)取处方量伏硫西汀昔萘酸盐、微晶纤维素、甘露醇、交联羧甲基纤维素钠、二氧化硅混合均匀;
(3)取处方量的硬脂酸镁加入步骤(2)所制得的混合颗粒中,混合均匀,压片即得。
对比应用实施例1氢溴酸伏硫西汀口崩片及其制备工艺
处方和制备工艺参见应用实施例1,区别仅在于将处方中的活性成分采用氢溴酸伏硫西汀替代。
实验例1崩解时限和溶出度
1、崩解时限的测定:取应用实施例1和对比应用实施例1样品,分别置于5ml烧杯中(预先加入2ml 37±1℃水),静置,观察样品至完全崩解并能通过2号筛的时间。结果见表2。
2、溶出度检测:取应用实施例1和对比应用实施例1样品,照溶出度测定法(中国药典2020版),以0.1mol/L盐酸溶液500ml为溶出介质,转速为每分钟50转,依法操作,在30分钟时,取溶液10ml,滤过,取续滤液作为供试品溶液;另取氢溴酸伏硫西汀适量,配制成浓度为30μg/ml的对照品溶液;以外标法检测伏硫西汀浓度,折合分子量,计算溶出度。结果见表2。
表2 崩解时限与平均溶出度
由表2可以看出,伏硫西汀昔萘酸盐制备的口崩片比氢溴酸伏硫西汀制备的口崩片崩解快,溶出度无明显差异。
实验例2口感测试
口感测试评价情况,见表3。
表3口感测试评价表
由表3可以看出,伏硫西汀昔萘酸盐制备的口崩片比氢溴酸伏硫西汀制备的口崩片口感好,可以有效掩盖伏硫西汀的苦涩味道,接受度高。
Claims (10)
1.一种伏硫西汀昔萘酸盐的晶型A,其特征在于,所述伏硫西汀昔萘酸盐结构式如下:
所述伏硫西汀昔萘酸盐晶型A的X-射线粉末衍射图谱在2θ(°)值为5.94±0.2、6.99±0.2、10.97±0.2、16.25±0.2、22.01±0.2处有衍射峰。
2.根据权利要求1所述的晶型A,其特征在于,所述的晶型A的X-射线粉末衍射图谱进一步在2θ(°)值为11.93±0.2、14.02±0.2、17.48±0.2、17.98±0.2、18.63±0.2、21.21±0.2、22.23±0.2的一处或多处有衍射峰。
3.根据权利要求2所述的晶型A,其特征在于,所述的晶型A的X-射线粉末衍射图谱进一步在2θ(°)值为19.67±0.2、24.06±0.2、24.41±0.2、25.02±0.2、25.75±0.2、26.04±0.2、28.39±0.2、28.64±0.2、28.84±0.2、31.77±0.2的一处或多处有衍射峰。
4.权利要求1-3任一所述的伏硫西汀昔萘酸盐的晶型A的制备方法,其特征在于,步骤如下:
将伏硫西汀溶于反应溶剂中,20℃~60℃条件下加入昔萘酸进行反应,反应结束后,降至室温,过滤分离得到固体,经真空干燥得伏硫西汀昔萘酸盐。
5.根据权利要求4所述的制备方法,其特征在于,所述的反应溶剂选自醇类、酮类、腈类、醚类、二氯甲烷、二甲基亚砜、N,N-二甲基乙酰胺、N,N-二甲基甲酰胺中的一种或几种,或其与水的组合物。
6.一种伏硫西汀的药物组合物,其特征在于,以权利要求1所述的伏硫西汀昔萘酸盐晶型A为药物主要活性成分。
7.根据权利要求6所述的药物组合物,其特征在于,所述药物组合物为口崩片。
8.根据权利要求7所述的药物组合物,其特征在于,所述口崩片包含填充剂、崩解剂、助流剂、润滑剂中的一种或几种。
9.根据权利要求8所述的药物组合物,其特征在于,所述填充剂为微晶纤维素(MCC)、微粉乙基纤维素、甘露醇、葡萄糖、山梨醇、乳糖和玉米淀粉中的一种或几种;
所述崩解剂为交联羧甲基纤维素钠、交联聚维酮、羧甲基淀粉钠、低取代羟丙纤维素中的一种或几种;
所述助流剂为二氧化硅、微粉硅胶的一种或几种;
所述润滑剂为滑石粉、硬脂酸镁、硬脂富马酸钠中的一种或两种。
10.根据权利要求1-3任一所述伏西汀昔萘酸盐晶型A在制备治疗中重度抑郁症的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310577912.4A CN116589434A (zh) | 2023-05-22 | 2023-05-22 | 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310577912.4A CN116589434A (zh) | 2023-05-22 | 2023-05-22 | 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116589434A true CN116589434A (zh) | 2023-08-15 |
Family
ID=87589502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310577912.4A Pending CN116589434A (zh) | 2023-05-22 | 2023-05-22 | 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116589434A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472906A (zh) * | 2006-06-16 | 2009-07-01 | H.隆德贝克有限公司 | 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪 |
CN103989650A (zh) * | 2014-06-13 | 2014-08-20 | 李雪梅 | 一种口腔崩解药物组合物及其制备方法 |
WO2015035802A1 (zh) * | 2013-09-12 | 2015-03-19 | 杭州普晒医药科技有限公司 | 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途 |
CN104610195A (zh) * | 2015-01-30 | 2015-05-13 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
CN104628677A (zh) * | 2015-03-16 | 2015-05-20 | 浙江大学 | 一种沃替西汀有机酸盐晶型及其制备方法 |
CN105534933A (zh) * | 2016-01-19 | 2016-05-04 | 美吉斯制药(厦门)有限公司 | 一种沃替西汀口腔崩解片及其制备方法 |
CN112125868A (zh) * | 2020-09-25 | 2020-12-25 | 中山万远新药研发有限公司 | 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途 |
-
2023
- 2023-05-22 CN CN202310577912.4A patent/CN116589434A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472906A (zh) * | 2006-06-16 | 2009-07-01 | H.隆德贝克有限公司 | 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪 |
WO2015035802A1 (zh) * | 2013-09-12 | 2015-03-19 | 杭州普晒医药科技有限公司 | 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途 |
CN104736526A (zh) * | 2013-09-12 | 2015-06-24 | 杭州普晒医药科技有限公司 | 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途 |
CN103989650A (zh) * | 2014-06-13 | 2014-08-20 | 李雪梅 | 一种口腔崩解药物组合物及其制备方法 |
CN104610195A (zh) * | 2015-01-30 | 2015-05-13 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
CN104628677A (zh) * | 2015-03-16 | 2015-05-20 | 浙江大学 | 一种沃替西汀有机酸盐晶型及其制备方法 |
CN105534933A (zh) * | 2016-01-19 | 2016-05-04 | 美吉斯制药(厦门)有限公司 | 一种沃替西汀口腔崩解片及其制备方法 |
CN112125868A (zh) * | 2020-09-25 | 2020-12-25 | 中山万远新药研发有限公司 | 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3750023B2 (ja) | アリピプラゾール無水物結晶、それらの製造方法及びそれらを含む製剤 | |
RU2137473C1 (ru) | Композиции, содержащие тонкоизмельченный небиволол | |
AU2005311714B2 (en) | Pharmaceutical composition containing an anti-nucleating agent | |
CN106967072B (zh) | 一种枸橼酸托法替布晶型化合物及其制备方法 | |
JPH02129124A (ja) | ジヒドロエルゴトキシン又はその酸付加塩の分散性錠剤及びその製造方法 | |
RU2317979C2 (ru) | Изолированная орторомбическая кристаллическая форма 4-[6-ацетил-3-[3-(4-ацетил-3-гидрокси-2-пропилфенилтио)пропокси]-2-пропил-фенокси]масляной кислоты и фармацевтическая композиция на ее основе | |
EP1902713A1 (en) | Pharmaceutical composition containing thiazolidinedione compound | |
CN116589434A (zh) | 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 | |
CN115300471B (zh) | 一种氨磺必利口腔崩解片及其制备方法 | |
CN115998687B (zh) | 一种姜黄素衍生物的固体分散体及其制备和应用 | |
CN114874210B (zh) | 阿哌沙班与富马酸的共晶体及其制备方法和应用 | |
CN105367551A (zh) | 达比加群酯乙醇酸盐及其制备方法和应用 | |
EP3875089A1 (en) | Tablet containing antitumor agent | |
US9051268B2 (en) | Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole | |
CN106176642B (zh) | 一种治疗呼吸系统疾病的分散片剂及其制备方法 | |
CN105440017A (zh) | 达比加群酯香草酸盐及其制备方法和应用 | |
EP2838513B1 (en) | Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole | |
EP4183390A1 (en) | An orodispersible pharmaceutical dosage form of edoxaban | |
CN114948969B (zh) | 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途 | |
CN102126973A (zh) | 一种二元酯酸的葡甲胺盐化合物,其制备方法和药物应用 | |
Prado et al. | EFAVIRENZ MICROCRYSTALS FOR DISSOLUTION ENHANCEMENT-FLUID-BED GRANULATION, SCALE-UP, TABLETING AND PHARMACOKINETICS | |
CN107865871B (zh) | 一种替吉奥组合物及其制备方法 | |
CN105348259A (zh) | 达比加群酯草酰乙酸盐及其制备方法和应用 | |
US20170136010A1 (en) | Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole | |
CN105348260A (zh) | 达比加群酯氢溴酸盐及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |